The CD38 monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone proved to be safe and showed an 81% response rate in patients with relapsed or refractory multiple myeloma, according to research presented at the 2015 ASH Annual Meeting.
AARP study finds that caregivers provide much more than basic care.
Although patients with multiple myeloma and other plasma cell disorders (PCDs) are routinely vaccinated against influenza, studies show that a one-time flu shot does not confer an adequate immune response in these high-risk patients.
The kinase inhibitor Ibrutinib (Imbruvica) is a more effective frontline therapy than the traditional chemotherapy chlorambucil in treating older treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), reducing the risk of death by 84%.
African American women can reduce their risk of developing ovarian cancer by following healthy dietary guidelines, a recent study has found.
Disparities in colorectal cancer deaths have had a significant impact on the national economy, with areas of low socioeconomic status experiencing the greatest losses, according to a study by researchers at the Centers for Disease Control and Prevention (CDC).
Patients with breast cancer who have received anthracycline-based (ANTHR) chemotherapy may be more likely to experience "chemobrain"-a cancer-related cognitive impairment that can affect memory, attention, and physical function-than those treated with nonanthracycline-based regimens.
If you're facing a lung cancer diagnosis, it's not uncommon to feel afraid, confused, overwhelmed or just plain alone.
With the survival rate of childhood cancer improving and advancements in treatments allowing more of the care to take place in the home, the responsibility of caregiving is increasingly being placed on family members.
Linked to expansion of health insurance coverage.
The FDA has approved Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone for patients with multiple myeloma who have received one to three prior therapies.
This video features the compelling stories of EC survivors: Brian Galgay and Karen Kent.
As I looked at Ms C, I was struck by the pensive but engaged smile she always sent my way. The same look continued as her daughter elaborated on her mother's condition.
The FDA has approved nivolumab (Opdivo) as a frontline treatment for patients with BRAF wild-type advanced melanoma, based on a substantial improvement in overall survival (OS) compared with dacarbazine in a phase III study.
The combination of Portrazza (necitumumab) with gemcitabine and cisplatin has been FDA approved as first-line therapy for patients with locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). The approval is based on findings from the phase III SQUIRE trial.
In 2007, Zoila Pasos found a lump in her breast when she was just a few weeks pregnant. Not long into the pregnancy, she miscarried. While she allowed her body time to heal, she had the lump checked and was told it was a benign cyst and nothing to worry about.
Based on an extension in overall survival (OS) in the CheckMate-025 trial, Opdivo (nivolumab) has been approved by the FDA for patients with metastatic renal cell carcinoma (RCC) following prior treatment with an anti-angiogenic therapy.
The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) has been fully approved by the FDA to treat patients with unresectable or metastatic BRAF-mutated melanoma. The approval is based on an extension in overall survival (OS) from two phase III studies.
As genetic testing becomes increasingly available, there will be a growing gap between the wide availability of testing and the relative importance of results to treatment decisions. In the current environment, there's more promise in precision medicine than practical applications in the exam room.
While immunotherapies continue to gain traction across multiple tumor types, including malignancies of the central nervous system, these agents are also associated with unique adverse events.
Compelling stories of esophageal cancer survivors.
Ninlaro (ixazomib) has been approved by the FDA in combination with Revlimid (lenalidomide) and dexamethasone as a treatment for patients with multiple myeloma who received at least one prior therapy.
In this interview to gain further insight into the flurry of FDA activity, Tim Turnham, executive director of the Melanoma Research Foundation, sheds light on the recent drug approvals and what's next for treating melanoma.
Women who develop ovarian cancer are more likely to have better outcomes if they took oral contraceptives prior to their diagnosis, according to a new study by researchers at Mayo Clinic.
Together, The Young Fellowship Grant and The Career Development Award total $200,000
While recent advances in breast cancer therapy have resulted in survival gains, many patients and survivors have an increased risk of cardiovascular adverse events following treatment.
Diagnosis and management guidelines.
The FDA granted an accelerated approval of the CD-38-targeted monoclonal antibody daratumumab (Darzalex)-the first monoclonal antibody to be approved for patients with multiple myeloma.
Many patients who have had melanoma do not conduct regular skin self-examinations, and those who do check themselves do not use sufficient tools or techniques.
The FDA has granted an accelerated approval for Tagrisso (osimertinib) to treat patients with advanced non–small cell lung cancer (NSCLC) positive the EGFR T790M mutation and whose disease worsened following a prior EGFR TKI.
